Recent meta-analyses have shown that the risk of venous thromboembolism (VTE) may increase in patients with immune-mediated inflammatory diseases treated with JAK inhibitors compared to placebo or tumor necrosis factor inhibitors, although these findings did not reach statistical significance ( Campanaro et al., 2023 ; Zhang et al., 2023 ).
← all excerpts
Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system.
2
—
—
The sentences
There was an increasing trend in the number of cases reported annually.